Long-term safety study for diabetic retinopathy gene therapy
Treatments studied
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This study follows people who already received an injection of RGX-314 (an experimental gene therapy) in a previous clinical trial for diabetic retinopathy, with or without swelling in the macula. It checks the long-term safety and how the treatment works over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in an earlier study of RGX-314 and received the injection.
- You have diabetic retinopathy (with or without diabetic macular edema).
- You are willing to give written consent and follow study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a follow-up for people who have already received an injection of RGX-314 for wet age-related macular degeneration (AMD) in an earlier trial. It looks at how the treatment works over a longer time and any long-term effects.
This study checks how well a previous eye treatment (RGX-314) lasts over time. There is also an extra “other eye” study for people with age-related macular degeneration affecting both eyes.
This trial tests a gene therapy injection into the eye to treat diabetic retinopathy (eye damage from diabetes) before it progresses. The goal is to slow or prevent vision loss and potentially delay the need for laser treatment or other injections.
This trial tests a one-time gene therapy injection for wet AMD that may reduce the need for regular eye injections. It is for people who have already responded to anti-VEGF injections but want a longer-lasting treatment.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
This trial tests an experimental gene therapy (OPGx-RDH12-1001) injected under the retina to treat a rare form of inherited vision loss called LCA caused by RDH12 gene mutations. It aims to see if the treatment is safe and tolerable for people with advanced vision loss.
Hear when a new Diabetic Retinopathy, DR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.